Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (26)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hartmann, J. T.
Right arrow Articles by Bokemeyer, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hartmann, J. T.
Right arrow Articles by Bokemeyer, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1017-1028, 2002
© 2002 European Society for Medical Oncology

Original Paper

Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors

J. T. Hartmann1,+, C. R. Nichols2, J.-P. Droz3, A. Horwich4, A. Gerl5, S. D. Fossa6, J. Beyer7, J. Pont8, L. Kanz1, L. Einhorn9 and C. Bokemeyer1

1 Tuebingen University Medical Center II, Tuebingen, Germany; 2 Oregon Health Sciences University, Portland, Oregon, USA; 3 Centre Léon-Berard, GETUG, Lyon Cedex, France; 4 The Royal Marsden Hospital, Sutton, UK; 5 Klinikum Großhadern, Munich, Germany; 6 The Norwegian Radium Hospital, Oslo, Norway; 7 Virchow Klinikum, Berlin, Germany; 8 Kaiser Franz Josef Spital, Vienna, Austria; 9 Indiana University, Indianapolis, IN, USA

Received 5 September 2001; revised and accepted 11 February 2002

Background:

This investigation evaluates prognostic variables in patients with seminomatous and non-seminomatous extragonadal germ-cell tumors (EGCT) in order to identify relevant factors for long-term outcome following cisplatin-based chemotherapy.

Patients and methods:

Patients from six countries treated at 11 centers in Europe and the USA from 1975 to 1996 were evaluated retrospectively. Uni- and multivariate analyses of prognostic variables for survival and for response to chemotherapy were performed.

Results:

Data were available for 635 EGCT patients, 104 with seminomatous and 524 with non-seminomatous EGCT (n = 7 not specified). For non-seminomatous EGCT the following independent adverse factors were identified: presence of either liver, lung or central nervous system metastases, primary mediastinal tumor or elevation of pretreatment ß-human gonadotropin; for extragonadal seminoma (only univariate) adverse factors were: presence of liver metastases, two or greater metastatic sites or International Germ Cell Cancer Collaborative Group (IGCCCG) grouping (intermediate versus good). Integration of these variables produced the following prognostic risk groupings: ‘excellent prognosis’, all seminomatous EGCT (89% 5-year survival rate); ‘intermediate low’, ‘intermediate high’ and ‘poor’, all non-seminomatous EGCT with a 69, 55 and 17% 5-year survival rate, respectively. The decreased survival among the different groups was due to a lower rate of favorable objective remissions and a higher rate of relapses. Classification and regression tree (CART) modeling confirmed histology and location of primary tumor as the major prognosticators. For the subgroup of patients with mediastinal non-seminoma, the 2-year survival rate ranged from 34 to 84%. Multivariate testing for the probability to respond to chemotherapy revealed non-seminomatous histology, primary mediastinal tumor site, and the presence of liver, lung or CNS metastases as independent adverse factors.

Conclusions:

In EGCT, prognostic variables for the outcome and for the response to chemotherapy could be identified, which in part differ from gonadal GCT. The proposed model might help to better understand the specific prognosis of EGCT and to tailor risk-adapted treatment strategies. In addition, CART analysis demonstrated the heterogenous prognosis of patients with mediastinal non-seminoma.

Key words: chemotherapy, extragonadal germ-cell tumors, mediastinal location, prognostic variables, response, retroperitoneal location


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
K. A. Kesler, K. M. Rieger, Z. T. Hammoud, L. E. Kruter, S. M. Perkins, M. W. Turrentine, B. P. Schneider, L. H. Einhorn, and J. W. Brown
A 25-Year Single Institution Experience With Surgery for Primary Mediastinal Nonseminomatous Germ Cell Tumors
Ann. Thorac. Surg., February 1, 2008; 85(2): 371 - 378.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. T. Hartmann, T. Gauler, B. Metzner, A. Gerl, J. Casper, O. Rick, M. Horger, J. Schleicher, G. Derigs, R. Mayer-Steinacker, et al.
Phase I/II Study of Sequential Dose-Intensified Ifosfamide, Cisplatin, and Etoposide Plus Paclitaxel As Induction Chemotherapy for Poor Prognosis Germ Cell Tumors by the German Testicular Cancer Study Group
J. Clin. Oncol., December 20, 2007; 25(36): 5742 - 5747.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J.-P. Lotz, B. Bui, F. Gomez, C. Theodore, A. Caty, K. Fizazi, G. Gravis, R. Delva, J. Peny, P. Viens, et al.
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial
Ann. Onc., March 1, 2005; 16(3): 411 - 418.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. J. Schmoll, R. Souchon, S. Krege, P. Albers, J. Beyer, C. Kollmannsberger, S. D. Fossa, N. E. Skakkebaek, R. de Wit, K. Fizazi, et al.
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)
Ann. Onc., September 1, 2004; 15(9): 1377 - 1399.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. P. Schneider, K. A. Kesler, J. A. Brooks, C. Yiannoutsos, and L. H. Einhorn
Outcome of Patients With Residual Germ Cell or Non-Germ Cell Malignancy After Resection of Primary Mediastinal Nonseminomatous Germ Cell Cancer
J. Clin. Oncol., April 1, 2004; 22(7): 1195 - 1200.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Amato
Development of a prognostic model for patients with extragonadal germ-cell tumors
Ann. Onc., July 1, 2002; 13(7): 991 - 992.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.